All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
What is the latest update on biomarkers for assessing GvHD?
Bookmark this article
During the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings), the GvHD Hub was pleased to speak to Carrie L. Kitko, Vanderbilt University Medical Center, Nashville, US. We asked, What is the latest update on biomarkers for assessing GvHD?
What is the latest update on biomarkers for assessing GvHD?
Kitko begins by explaining how treatment response at Day 28 is used as a surrogate marker for long-term outcomes in clinical trials, despite limited accuracy. Kitko then discusses the Mount Sinai Acute GvHD International Consortium (MAGIC) algorithm, which can be used to estimate a patient's probability of 6-month nonrelapse mortality. Finally, Kitko talks about potential new biomarkers that were discussed at the Tandem Meetings.
Your opinion matters
8 votes - 23 days left ...
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox